Leveraging Clinical Data to Evaluate a Single Dose Intravitreal Administration of AVD-104

Time: 3:00 pm
day: Conference Day 2


  • Assessing the dose escalation and safety data
  • Highlighting the benefits of using our chosen molecule
  • Outlining the trial design for the 2 year trial with a 12 month primary endpoint